{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:56:15Z","timestamp":1778806575217,"version":"3.51.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T00:00:00Z","timestamp":1428537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40265-015-0385-y","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T06:54:04Z","timestamp":1428476044000},"page":"777-796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"75","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,9]]},"reference":[{"issue":"1","key":"385_CR1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","volume":"87","author":"JE Shaw","year":"2010","unstructured":"Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4\u201314.","journal-title":"Diabetes Res Clin Pract."},{"issue":"15","key":"385_CR2","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1517\/14656566.2013.824966","volume":"14","author":"CF Deacon","year":"2013","unstructured":"Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047\u201358.","journal-title":"Expert Opin Pharmacother."},{"key":"385_CR3","first-page":"989","volume":"7","author":"A Capuano","year":"2013","unstructured":"Capuano A, Sportiello L, Maiorino MI, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy: focus on alogliptin. Drug Des Dev Ther. 2013;7:989\u20131001.","journal-title":"Drug Des Dev Ther."},{"key":"385_CR4","unstructured":"Takeda Pharmaceuticals America Inc. Nesina (alogliptin) tablets: US prescribing information. 2013. http:\/\/www.takeda.us\/products\/default.aspx . Accessed 3 Mar 2015."},{"key":"385_CR5","unstructured":"European Medicines Agency. Vipidia (alogliptin): EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/ . Accessed 3 Mar 2015."},{"key":"385_CR6","unstructured":"Takeda Pharmaceuticals America Inc. Kazano (alogliptin and metformin HCl) tablets for oral administration: US prescribing information. 2013. http:\/\/www.takeda.us\/products\/default.aspx . Accessed 3 Mar 2015."},{"key":"385_CR7","unstructured":"European Medicines Agency. Vipdomet (alogliptin\/metformin): EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/ . Accessed 3 Mar 2015."},{"key":"385_CR8","unstructured":"Takeda Pharmaceuticals America Inc. Oseni (alogliptin and pioglitazone) tablets: US prescribing information. 2013. http:\/\/www.takeda.us\/products\/default.aspx . Accessed 3 Mar 2015."},{"key":"385_CR9","unstructured":"European Medicines Agency. Incresync (alogliptin\/pioglitazone): EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/ . Accessed 3 Mar 2015."},{"issue":"10","key":"385_CR10","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/jm070104l","volume":"50","author":"J Feng","year":"2007","unstructured":"Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50(10):2297\u2013300.","journal-title":"J Med Chem."},{"key":"385_CR11","unstructured":"Christopher RJ, Davenport JM, Gwaltney S, et al. Pharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, in rats, dogs, and monkeys [abstract no. 452-P]. In: 66th Annual Scientific Sessions of the American Diabetes Association. 2006."},{"issue":"9","key":"385_CR12","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1185\/03007995.2011.599371","volume":"27","author":"Y Seino","year":"2011","unstructured":"Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9):1781\u201392.","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"385_CR13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clinthera.2008.03.004","volume":"30","author":"P Covington","year":"2008","unstructured":"Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499\u2013512.","journal-title":"Clin Ther."},{"key":"385_CR14","unstructured":"Hirayama M, Matsuno K, Fujita H, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects [abstract no. 521-P]. In: 68th Scientific Sessions of the American Diabetes Association. 2008."},{"issue":"3","key":"385_CR15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.clinthera.2008.03.005","volume":"30","author":"R Christopher","year":"2008","unstructured":"Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513\u201327.","journal-title":"Clin Ther."},{"issue":"4","key":"385_CR16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1530\/EJE-13-0639","volume":"170","author":"DH Raalte Van","year":"2014","unstructured":"Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565\u201374.","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"385_CR17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.2040-1124.2012.00226.x","volume":"3","author":"Y Seino","year":"2012","unstructured":"Seino Y, Hiroi S, Hirayama M, et al. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Investig. 2012;3(6):517\u201325.","journal-title":"J Diabetes Investig."},{"issue":"10","key":"385_CR18","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1463-1326.2012.01620.x","volume":"14","author":"Y Seino","year":"2012","unstructured":"Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14(10):927\u201336.","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"385_CR19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12258","volume":"16","author":"RE Pratley","year":"2014","unstructured":"Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014;16(7):613\u201321.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"385_CR20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2008.01933.x","volume":"63","author":"MA Nauck","year":"2009","unstructured":"Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46\u201355.","journal-title":"Int J Clin Pract."},{"issue":"11","key":"385_CR21","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1463-1326.2011.01460.x","volume":"13","author":"K Kaku","year":"2011","unstructured":"Kaku K, Itayasu T, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11):1028\u201335.","journal-title":"Diabetes Obes Metab."},{"issue":"Suppl 3","key":"385_CR22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1185\/03007995.2011.614936","volume":"27","author":"Y Seino","year":"2011","unstructured":"Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011;27(Suppl 3):21\u20139.","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"385_CR23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12020-012-9596-0","volume":"41","author":"E Kutoh","year":"2012","unstructured":"Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naive type 2 diabetes: a randomized, control trial. Endocrine. 2012;41(3):435\u201341.","journal-title":"Endocrine."},{"issue":"4","key":"385_CR24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00125-011-2447-3","volume":"55","author":"B Eliasson","year":"2012","unstructured":"Eliasson B, M\u00f6ller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and\/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915\u201325.","journal-title":"Diabetologia."},{"key":"385_CR25","first-page":"493","volume":"6","author":"A Jurczyk","year":"2013","unstructured":"Jurczyk A, Dilorio P, Brostowin D, et al. Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2r\u03b3 null mice treated with alogliptin. Diabetes Metab Syndr Obes. 2013;6:493\u20139.","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"4","key":"385_CR26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1463-1326.2010.01354.x","volume":"13","author":"X Zhang","year":"2011","unstructured":"Zhang X, Wang Z, Huang Y, et al. Effects of chronic administration of alogliptin on the development of diabetes and \u03b2-cell function in high fat diet\/streptozotocin diabetic mice. Diabetes Obes Metab. 2011;13(4):337\u201347.","journal-title":"Diabetes Obes Metab."},{"issue":"Suppl 1","key":"385_CR27","first-page":"143","volume":"57","author":"P Fleck","year":"2008","unstructured":"Fleck P, Christopher R, Covington P. Efficacy and safety of alogliptin monotherapy over 12\u00a0weeks in patients with type 2 diabetes [abstract no. 479-P]. Diabetes. 2008;57(Suppl 1):143.","journal-title":"Diabetes."},{"issue":"10","key":"385_CR28","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1185\/03007990903156111","volume":"25","author":"RE Pratley","year":"2009","unstructured":"Pratley RE, Reusch JE-B, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361\u201371.","journal-title":"Curr Med Res Opin."},{"issue":"12","key":"385_CR29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","volume":"11","author":"J Rosenstock","year":"2009","unstructured":"Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11(12):1145\u201352.","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"385_CR30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2008.01016.x","volume":"11","author":"RE Pratley","year":"2009","unstructured":"Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11(2):167\u201376.","journal-title":"Diabetes Obes Metab."},{"key":"385_CR31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1475-2840-12-8","volume":"12","author":"Y Noda","year":"2013","unstructured":"Noda Y, Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol. 2013;12:8.","journal-title":"Cardiovasc Diabetol."},{"key":"385_CR32","unstructured":"Kato S, Kirigaya H, Gyotoku D, et al. DPP-4 inhibition by alogliptin improves the coronary flow reserve evaluated by phase contrast cine magnetic resonance imaging in type 2 diabetic patients with coronary artery disease [abstract no. 16542]. In: 86th Annual Scientific Sessions of the American Heart Association. 2013."},{"key":"385_CR33","doi-asserted-by":"crossref","unstructured":"Yamauchi Y, Tunekawa S, Seino Y, et al. The effect of DPP-4 inhibitor, alogliptin, on bone metabolism in patients with type 2 diabetes mellitus [abstract no. 1071-P]. In: 73rd Annual Scientific Sessions of the American Diabetes Association. 2013.","DOI":"10.1007\/s12467-013-0039-1"},{"issue":"9","key":"385_CR34","first-page":"1207","volume":"47","author":"A Karim","year":"2007","unstructured":"Karim A, Harris S, Fleck P, et al. Assessment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, and warfarin at steady state [abstract no. 106]. J Clin Pharmacol. 2007;47(9):1207.","journal-title":"J Clin Pharmacol."},{"issue":"1","key":"385_CR35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5414\/CPP48046","volume":"48","author":"A Karim","year":"2010","unstructured":"Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010;48(1):46\u201358.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"385_CR36","unstructured":"European Medicines Agency. Vipidia (alogliptin): EU public assessment report. 2013. http:\/\/www.ema.europa.eu\/ . Accessed 3 Mar 2015."},{"key":"385_CR37","unstructured":"Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [abstract no. 538-P]. In: 68th Annual Scientific Sessions of the American Diabetes Association. 2008."},{"issue":"9","key":"385_CR38","first-page":"1207","volume":"47","author":"A Karim","year":"2007","unstructured":"Karim A, Fleck P, Dorsey D, et al. Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment [abstract no. 107]. J Clin Pharmacol. 2007;47(9):1207.","journal-title":"J Clin Pharmacol."},{"issue":"Suppl 1","key":"385_CR39","first-page":"S13","volume":"83","author":"A Karim","year":"2008","unstructured":"Karim A, Fleck P, Harrell RE, et al. Effects of age, race, and gender on the pharmacokinetics and pharmacodynamics of alogliptin, a novel and highly selective dipeptidyl peptidase-4 inhibitor in healthy subjects [abstract no. PI-14]. Clin Pharmacol Ther. 2008;83(Suppl 1):S13.","journal-title":"Clin Pharmacol Ther."},{"issue":"9","key":"385_CR40","first-page":"1207","volume":"47","author":"A Karim","year":"2007","unstructured":"Karim A, Fleck P, Harris S, et al. Effect of fluconazole, ketoconazole, and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects [abstract no. 105]. J Clin Pharmacol. 2007;47(9):1207.","journal-title":"J Clin Pharmacol."},{"issue":"10","key":"385_CR41","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1177\/0091270009338938","volume":"49","author":"A Karim","year":"2009","unstructured":"Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009;49(10):1210\u20139.","journal-title":"J Clin Pharmacol."},{"issue":"Suppl 1","key":"385_CR42","first-page":"S12","volume":"83","author":"A Karim","year":"2008","unstructured":"Karim A, Fleck P, Harris S, et al. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects [abstract no. PI-13]. Clin Pharmacol Ther. 2008;83(Suppl 1):S12\u20133.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 1","key":"385_CR43","first-page":"S14","volume":"83","author":"A Karim","year":"2008","unstructured":"Karim A, Fleck P, Harris S, et al. Assessment of drug interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects [abstract no. PI-17]. Clin Pharmacol Ther. 2008;83(Suppl 1):S14.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 1","key":"385_CR44","first-page":"S13","volume":"83","author":"A Karim","year":"2008","unstructured":"Karim A, Chiselko P, Fleck P, et al. Lack of effect of cyclosporine on the single-dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy subjects [abstract no. PI-15]. Clin Pharmacol Ther. 2008;83(Suppl 1):S13.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 1","key":"385_CR45","first-page":"S14","volume":"83","author":"A Karim","year":"2008","unstructured":"Karim A, Copa A, Fleck P, et al. Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (Ortho-Novum\u00ae 1\/35) in healthy adult female subjects [abstract no. PI-16]. Clin Pharmacol Ther. 2008;83(Suppl 1):S14.","journal-title":"Clin Pharmacol Ther."},{"issue":"12","key":"385_CR46","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/dc08-1035","volume":"31","author":"RA DeFronzo","year":"2008","unstructured":"DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315\u20137.","journal-title":"Diabetes Care."},{"key":"385_CR47","unstructured":"Ji Q, Han P, Li C, et al. Efficacy and safety of alogliptin in subjects with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 study in mainland China, Taiwan and Hong Kong [abstract no. 915]. In: 49th Annual Meeting of the European Association for the Study of Diabetes. 2013."},{"issue":"11","key":"385_CR48","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.2337\/dc10-0159","volume":"33","author":"J Rosenstock","year":"2010","unstructured":"Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406\u20138.","journal-title":"Diabetes Care."},{"issue":"12","key":"385_CR49","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2011.01463.x","volume":"13","author":"E Bosi","year":"2011","unstructured":"Bosi E, Ellis GC, Wilson CA, et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088\u201396.","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"385_CR50","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1210\/jc.2011-2243","volume":"97","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1615\u201322.","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"385_CR51","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12102","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15(10):906\u201314.","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"385_CR52","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/dom.12377","volume":"16","author":"S Prato Del","year":"2014","unstructured":"Del Prato S, Camisasca R, Wilson C, et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239\u201346.","journal-title":"Diabetes Obes Metab."},{"issue":"15","key":"385_CR53","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1517\/14656566.2014.956722","volume":"15","author":"K Kaku","year":"2014","unstructured":"Kaku K, Mori M, Kanoo T, et al. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother. 2014;15(15):2121\u201330.","journal-title":"Expert Opin Pharmacother."},{"issue":"1\u20132","key":"385_CR54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000351678","volume":"123","author":"Y Nakamura","year":"2013","unstructured":"Nakamura Y, Inagaki M, Shimizu T, et al. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract. 2013;123(1\u20132):46\u201351.","journal-title":"Nephron Clin Pract."},{"issue":"3","key":"385_CR55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14656566.2013.761690","volume":"14","author":"Y Fujii","year":"2013","unstructured":"Fujii Y, Abe M, Higuchi T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother. 2013;14(3):259\u201367.","journal-title":"Expert Opin Pharmacother."},{"issue":"14","key":"385_CR56","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med."},{"key":"385_CR57","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015. doi: 10.1016\/S0140-6736(14)62225-X .","journal-title":"Lancet."},{"key":"385_CR58","unstructured":"Data on file, Takeda, 2014."},{"issue":"6","key":"385_CR59","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364\u201379.","journal-title":"Diabetes Care."},{"key":"385_CR60","doi-asserted-by":"crossref","unstructured":"Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36 Suppl 1:S11\u201366.","DOI":"10.2337\/dc13-S011"},{"issue":"2","key":"385_CR61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/endp.19.2.a38267720403k242","volume":"19","author":"AJ Garber","year":"2013","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327\u201336.","journal-title":"Endocr Pract."},{"issue":"2","key":"385_CR62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3810\/hp.2013.04.1059","volume":"41","author":"B Charbonnel","year":"2013","unstructured":"Charbonnel B, Schweizer A, Dejager S. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract (Minneap). 2013;41(2):93\u2013107.","journal-title":"Hosp Pract (Minneap)."},{"key":"385_CR63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6823-13-9","volume":"13","author":"A Berhan","year":"2013","unstructured":"Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocrine Disord. 2013;13:9.","journal-title":"BMC Endocrine Disord."},{"issue":"1","key":"385_CR64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/hp.2011.02.369","volume":"39","author":"I Bourdel-Marchasson","year":"2011","unstructured":"Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract. 2011;39(1):7\u201321.","journal-title":"Hosp Pract."},{"issue":"3","key":"385_CR65","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1517\/14656560802694713","volume":"10","author":"RE Pratley","year":"2009","unstructured":"Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2009;10(3):503\u201312.","journal-title":"Expert Opin Pharmacother."},{"issue":"14","key":"385_CR66","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med."},{"key":"385_CR67","unstructured":"McMurray JJV, Ponikowski P, Bolli GB, et al. The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD) [late-breaking abstract]. In: Heart Failure 2013. 2013."},{"issue":"6","key":"385_CR68","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ahj.2013.09.003","volume":"166","author":"JB Green","year":"2013","unstructured":"Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(6):983\u20139.","journal-title":"Am Heart J."},{"issue":"4","key":"385_CR69","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1479164112475102","volume":"10","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diabetes Vasc Dis Res. 2013;10(4):289\u2013301.","journal-title":"Diabetes Vasc Dis Res."},{"issue":"12","key":"385_CR70","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5551\/jat.18333","volume":"20","author":"N Katakami","year":"2013","unstructured":"Katakami N, Mita T, Yoshii H, et al. Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). J Atheroscler Thromb. 2013;20(12):893\u2013902.","journal-title":"J Atheroscler Thromb."},{"issue":"7","key":"385_CR71","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","volume":"173","author":"S Singh","year":"2013","unstructured":"Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534\u20139.","journal-title":"JAMA Intern Med."},{"issue":"3","key":"385_CR72","first-page":"491","volume":"51","author":"J-L Faillie","year":"2014","unstructured":"Faillie J-L, Babai S, Cr\u00e9pin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case\/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 2014;51(3):491\u20137.","journal-title":"Acta Diabetol."},{"issue":"4","key":"385_CR73","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14740338.2013.793671","volume":"12","author":"A Scheen","year":"2013","unstructured":"Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf. 2013;12(4):545\u201357.","journal-title":"Expert Opin Drug Saf."},{"issue":"7","key":"385_CR74","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","volume":"62","author":"AE Butler","year":"2013","unstructured":"Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595\u2013604.","journal-title":"Diabetes."},{"issue":"2","key":"385_CR75","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MEG.0b013e32835af154","volume":"25","author":"L Yang","year":"2013","unstructured":"Yang L, He Z, Tang X, et al. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25(2):225\u201331.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"12","key":"385_CR76","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1463-1326.2012.01667.x","volume":"14","author":"KG Brodovicz","year":"2012","unstructured":"Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012;14(12):1123\u20138.","journal-title":"Diabetes Obes Metab."},{"issue":"Suppl 3","key":"385_CR77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1185\/03007995.2011.602964","volume":"27","author":"M Monami","year":"2011","unstructured":"Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl 3):57\u201364.","journal-title":"Curr Med Res Opin."},{"key":"385_CR78","doi-asserted-by":"crossref","unstructured":"Gokhale M, Sturmer T, Gray C, et al. Dipeptidyl peptidase 4 inhibitors and comparative pancreatic cancer risk [abstract no. 111-LB]. In: 73rd Scientific Sessions of the American Diabetes Association. 2013.","DOI":"10.1111\/dom.12379"},{"issue":"11","key":"385_CR79","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.clinthera.2011.09.028","volume":"33","author":"KR Richard","year":"2011","unstructured":"Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609\u201329.","journal-title":"Clin Ther."},{"issue":"1","key":"385_CR80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/dom.12176","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(1):48\u201356.","journal-title":"Diabetes Obes Metab."},{"key":"385_CR81","doi-asserted-by":"crossref","first-page":"g2780","DOI":"10.1136\/bmj.g2780","volume":"348","author":"JL Faillie","year":"2014","unstructured":"Faillie JL, Azoulay L, Patenaude V, et al. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348:g2780.","journal-title":"BMJ."},{"issue":"9","key":"385_CR82","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370(9):794\u20137.","journal-title":"N Engl J Med."},{"issue":"11","key":"385_CR83","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","volume":"34","author":"M Monami","year":"2011","unstructured":"Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474\u20136.","journal-title":"Diabetes Care."},{"issue":"1","key":"385_CR84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0897190014522063","volume":"28","author":"AB Marino","year":"2015","unstructured":"Marino AB, Cole SW. Alogliptin: safety, efficacy, and clinical implications. J Pharm Pract. 2015;28(1):99\u2013106.","journal-title":"J Pharm Pract."},{"issue":"3","key":"385_CR85","doi-asserted-by":"crossref","first-page":"A160","DOI":"10.1016\/j.jval.2013.03.797","volume":"16","author":"M Bron","year":"2013","unstructured":"Bron M, Ferrufino CP, Samyshkin Y, et al. Evaluation of the pharmacy budget impact of alogliptin plus pioglitazone fixed dose combination in the treatment of type-2 diabetes mellitus [abstract no. PDB25]. Value Health. 2013;16(3):A160.","journal-title":"Value Health."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0385-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0385-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0385-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T23:15:45Z","timestamp":1566515745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0385-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,9]]},"references-count":85,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0385-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,9]]}}}